NURS 6630 Week 7 psychosis case analysis example

Weight Already Rising Before the First Dose: A Receptor-Based Case Analysis of Antipsychotic Choice for a 19-Year-Old With First-Episode Psychosis and a Family History of Diabetes

Student Name

College of Nursing, Walden University

NURS 6630: Neurobiology and Psychopharmacology for Psychiatric Mental Health Advanced Practice Nursing

Instructor Name

Month Day, Year

Weight Already Rising Before the First Dose: A Receptor-Based Case Analysis of Antipsychotic Choice for a 19-Year-Old With First-Episode Psychosis and a Family History of Diabetes

The Composite Patient

A nineteen-year-old college student has heard voices commenting on his actions for four months, has stopped attending classes and has withdrawn from friends, spending most days in his room. He is suspicious of his roommates and believes his phone is monitored. There is no substance use on history or urine screen, and a medical workup is unremarkable. His mother and maternal grandmother have type 2 diabetes. He has gained 5 kg in half a year, blaming late-night eating, and his waist circumference is above the healthy range for his height. He has never taken an antipsychotic. The case asks for an antipsychotic choice reasoned from receptor pharmacology, stated at class level without doses.

Receptors, Pathways and Effects

Antipsychotic benefit for positive symptoms is linked to blocking dopamine D2 receptors in the mesolimbic pathway, where excess dopamine signaling is thought to underlie hallucinations and delusions. The same D2 blockade acts in other pathways where it is not wanted. In the nigrostriatal pathway it produces movement effects, including parkinsonism, dystonia and akathisia, an inner restlessness that patients find distressing and that can drive nonadherence. In the tuberoinfundibular pathway it removes dopamine's inhibition of prolactin release, raising prolactin (Stahl, 2021).

Second-generation agents add 5-HT2A antagonism, which releases dopamine in some pathways and is thought to reduce movement effects and prolactin elevation at a given level of D2 blockade. Many also block histamine H1 and serotonin 5-HT2C receptors, and these actions predict increased appetite and weight gain, with downstream effects on glucose and lipids. Partial agonists at the D2 receptor take a different route: they reduce dopamine signaling where it is excessive while providing some signaling where it is low, which predicts less prolactin elevation and fewer metabolic effects but a notable risk of akathisia (Stahl, 2021).

Two Agents Compared

Agent A is a second-generation antagonist with strong D2 and 5-HT2A blockade plus strong H1 and 5-HT2C blockade. It is effective for positive symptoms and often sedating, which could help his poor sleep, but its receptor profile predicts substantial weight gain and metabolic risk. Agent B is a D2 partial agonist with minimal H1 and modest 5-HT2C activity. It is effective for positive symptoms in many patients, predicts less weight gain and less prolactin elevation, and carries a higher likelihood of akathisia, especially early.

The choice is Agent B. For a young man already gaining weight, with abdominal adiposity and a strong family history of diabetes, the metabolic consequences of Agent A's receptor profile are the risk most likely to shorten his life, and they accumulate silently. A consensus statement on antipsychotics, obesity and diabetes identified differences between agents in weight gain and metabolic risk and called for baseline and follow-up monitoring for all patients (American Diabetes Association et al., 2004). Akathisia is the cost the analysis accepts, because it is visible, can be asked about and assessed, and can be managed or prompt a change, while metabolic harm is harder to reverse once established.

Monitoring

Metabolic: weight and body mass index at baseline and at every visit in the first three months, waist circumference, blood pressure, a fasting glucose or A1c test and lipid measurements at baseline and at twelve weeks, then at least annually, following the consensus schedule (American Diabetes Association et al., 2004). Movement: at each early visit, a direct question about restlessness and an observed assessment using a standard akathisia rating scale, with a plan to respond if it appears, and the Abnormal Involuntary Movement Scale at baseline and periodically for other movement effects. Symptoms and function: a standard rating of positive symptoms and a question about return to classes or activities. Prolactin is checked if symptoms suggest elevation.

When Would Clozapine Enter the Plan?

Not now. Clozapine has the strongest evidence for schizophrenia that has not responded to two adequate antipsychotic trials, and practice guidance recommends it for treatment-resistant illness and for persistent suicide risk (Keepers et al., 2020). It carries significant metabolic risk and a boxed warning for severe neutropenia, which is why it requires regular blood monitoring, so it would not be a first choice for this patient. The analysis names it so the family knows that, if the first agents do not work, a well-supported option remains.

References

American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity. (2004). Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care, 27(2), 596-601. https://doi.org/10.2337/diacare.27.2.596

Keepers, G. A., Fochtmann, L. J., Anzia, J. M., Benjamin, S., Lyness, J. M., Mojtabai, R., Servis, M., Walaszek, A., Buckley, P., Lenzenweger, M. F., Young, A. S., Degenhardt, A., & Hong, S.-H. (2020). The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia. American Journal of Psychiatry, 177(9), 868-872. https://doi.org/10.1176/appi.ajp.2020.177901

Stahl, S. M. (2021). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (5th ed.). Cambridge University Press.